Legal Representation
Attorney
Christina M. Licursi
USPTO Deadlines
Next Deadline
2093 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250916)
Due Date
September 16, 2031
Grace Period Ends
March 16, 2032
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
45 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Sep 16, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Sep 16, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Aug 27, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Aug 27, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Aug 3, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Apr 10, 2025 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Aug 3, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Apr 10, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Oct 10, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 10, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Oct 10, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Oct 10, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 11, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 10, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Apr 10, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Apr 10, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 29, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Feb 29, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Feb 29, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Oct 10, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Aug 15, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 15, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 26, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 11, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 11, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jul 11, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jul 11, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jul 11, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jul 11, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jul 11, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jul 11, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jul 11, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jul 10, 2023 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN | Loading... |
| May 30, 2023 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
| May 17, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 16, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 15, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 15, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 16, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 16, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 16, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 10, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 20, 2022 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Oct 19, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 6, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceuticals for use in the treatment and diagnosis of cancer; therapeutic pharmaceuticals for use in the treatment and diagnosis of cancer; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids and tissue samples for the treatment and diagnosis of cancer; pharmaceutical preparations comprised of medical diagnostic reagents and assays for testing of bodily fluids and tissue samples for the treatment and diagnosis of cancer
First Use Anywhere:
20240300
First Use in Commerce:
20240300
Class 042
Scientific research, pharmaceutical research, medical research; technical scientific consultation and product development for others in the field of biotechnology and development of pharmaceuticals
First Use Anywhere:
20240300
First Use in Commerce:
20240300
Class 044
Medical diagnostic services for use in the treatment and diagnosis of cancer
First Use Anywhere:
20240300
First Use in Commerce:
20240300
Additional Information
Design Mark
The mark consists of the words "HARBINGER HEALTH" to the right of nine dots which together form a square, with seven of the dots appearing larger so as to form a letter "H".
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"HEALTH"